<h2 data-section-id="zod3x2" data-start="0" data-end="29"><strong>Febrile Neutropenia Market</strong></h2>
<p data-start="31" data-end="802">The <a href="https://www.delveinsight.com/report-store/febrile-neutropenia-market"><strong>Febrile Neutropenia market</strong></a> across the 7MM is witnessing steady growth, driven by rising chemotherapy utilization, increasing cancer incidence, and improved clinical awareness. The market size reached nearly USD 4.7 billion in 2025 and is expected to grow at a CAGR of 3.2% during 2026&ndash;2036. Long-acting granulocyte colony-stimulating factor (G-CSF) therapies, including <a href="https://www.delveinsight.com/report-store/biosimilars-market"><strong>biosimilars</strong></a> and lipegfilgrastim, accounted for the largest revenue share, generating around USD 4.1 billion in 2025. Hospital-based management remains dominant due to the high-risk nature of febrile neutropenia. Additionally, ongoing clinical research, supportive reimbursement policies, and strategic collaborations among pharmaceutical companies continue to strengthen the competitive landscape.</p>
<h3 data-section-id="1ou85va" data-start="804" data-end="829"><strong>Key Market Highlights</strong></h3>
<ul data-start="830" data-end="1095">
<li data-section-id="1s9cxxm" data-start="830" data-end="874">7MM market size in 2025: USD 4.7 Billion</li>
<li data-section-id="1ulu6uf" data-start="875" data-end="910">Forecast CAGR (2026&ndash;2036): 3.2%</li>
<li data-section-id="1t9hi0t" data-start="911" data-end="967">Long-acting G-CSF segment generated ~USD 4.1 Billion</li>
<li data-section-id="7kk5kg" data-start="968" data-end="1041">Major drivers include increasing cancer burden and chemotherapy usage</li>
<li data-section-id="zchq9i" data-start="1042" data-end="1095">Improved diagnosis rates support market expansion</li>
</ul>
<h2 data-section-id="18kprll" data-start="1102" data-end="1137"><strong>Febrile Neutropenia Epidemiology</strong></h2>
<p data-start="1139" data-end="1885"><a href="https://www.delveinsight.com/report-store/febrile-neutropenia-epidemiology-forecast"><strong>Febrile neutropenia</strong></a> remains a major complication among cancer patients receiving chemotherapy. In 2025, total chemotherapy usage across the 7MM was estimated at approximately 1.9 million cases annually. The EU4 and the UK represented the largest share with 47%, followed by the US with 38% and Japan with 15%. In the United States alone, chemotherapy-associated febrile neutropenia cases reached nearly 692,000. Epidemiological findings indicate a higher incidence among males compared to females. Most patients fall within the intermediate-risk category, while high-risk cases remain comparatively limited. Cardiovascular disease represented the highest comorbidity-specific burden, whereas liver disease showed the lowest incidence association.</p>
<h3 data-section-id="1cq272w" data-start="1887" data-end="1912"><strong>Epidemiology Insights</strong></h3>
<ul data-start="1913" data-end="2194">
<li data-section-id="mh07po" data-start="1913" data-end="1970">Total chemotherapy usage in 7MM: 1.9 million annually</li>
<li data-section-id="1c8ixp3" data-start="1971" data-end="2013">US chemotherapy-associated cases: 692K</li>
<li data-section-id="kimq37" data-start="2014" data-end="2066">EU4 and UK contributed 47% of chemotherapy usage</li>
<li data-section-id="26jy7f" data-start="2067" data-end="2122">Male patients show relatively higher susceptibility</li>
<li data-section-id="39ou68" data-start="2123" data-end="2194">Intermediate-risk patients represent the largest population segment</li>
</ul>
<h2 data-section-id="c8wwpg" data-start="2201" data-end="2251"><strong>Febrile Neutropenia Pipeline and Emerging Drugs</strong></h2>
<p data-start="2253" data-end="3080">The <a href="https://www.delveinsight.com/report-store/febrile-neutropenia-pipeline-insight"><strong>Febrile Neutropenia pipeline</strong></a> remains limited but continues to evolve through supportive care innovations and novel immunomodulatory approaches. Current management primarily relies on empiric broad-spectrum antibiotics and G-CSF agents such as filgrastim, pegfilgrastim, lenograstim, and lipegfilgrastim. Approved therapies include RYZNEUTA, LONQUEX, GRANIX, ROLVEDON, and G-LASTA. Among emerging therapies, Plinabulin by <span class="whitespace-normal">BeyondSpring Pharmaceuticals</span> is gaining attention for its selective immunomodulating microtubule-binding agent (SIMBA) mechanism administered via IV infusion. Despite ongoing research, slow pipeline progression, delayed clinical trials, antimicrobial resistance, and gaps in diagnosis and risk stratification continue to challenge innovation within the febrile neutropenia treatment landscape.</p>
<h3 data-section-id="en7pbd" data-start="3082" data-end="3113"><strong>Approved and Emerging Drugs</strong></h3>
<ul data-start="3114" data-end="3495" data-is-last-node="" data-is-only-node="">
<li data-section-id="rfoh3n" data-start="3114" data-end="3188">RYZNEUTA &ndash; Evive Biotech/Acrotech Biopharma/APOGEPHA Arzneimittel GmbH</li>
<li data-section-id="5zezki" data-start="3189" data-end="3240">LONQUEX &ndash; <span class="whitespace-normal">Teva Pharmaceutical</span></li>
<li data-section-id="1hlj0kt" data-start="3241" data-end="3291">GRANIX &ndash; <span class="whitespace-normal">Teva Pharmaceutical</span></li>
<li data-section-id="fnyzhv" data-start="3292" data-end="3331">ROLVEDON &ndash; Spectrum Pharmaceuticals</li>
<li data-section-id="hho239" data-start="3332" data-end="3423">G-LASTA &ndash; <span class="whitespace-normal">Kyowa Kirin</span> / <span class="whitespace-normal">Terumo Corporation</span></li>
<li data-section-id="11y2pq2" data-start="3424" data-end="3495" data-is-last-node="">Plinabulin &ndash; <span class="whitespace-normal">BeyondSpring Pharmaceuticals</span> (Emerging Therapy)</li>
</ul>

Febrile Neutropenia Market

Febrile Neutropenia Market Infographic

Febrile Neutropenia Market Thumbnail

Febrile Neutropenia Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape